Update on the management of acute graft-versus-host disease

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of review: Acute graft-versus-host disease is one of the commonest complications after allogeneic stem cell transplantation. Recent advances in its prevention and therapy are giving new hope to patients with this disease. This review covers the major advances in prophylaxis and therapy for this problem. Recent findings: The use of novel approaches for prophylaxis such as posttransplant cyclophosphamide and non-methotrexate-containing regimens is discussed. The results of therapy with new agents such as pentostatin, pulse cyclophosphamide, long-wavelength ultraviolet A phototherapy, and monoclonal antibodies such as denileukin diftitox or etanercept are reviewed. Summary: Without question, outcome in patients who develop graft-versus-host disease is improving. With better supportive care, and more effective prophylaxis and therapy, these patients have an improved chance for full recovery. Patients should be enrolled, when possible, in studies aimed to prevent and treat graft-versus-host disease.

Original languageEnglish (US)
Pages (from-to)120-125
Number of pages6
JournalCurrent opinion in oncology
Volume18
Issue number2
DOIs
StatePublished - Mar 1 2006

Keywords

  • Acute graft-versus-host disease
  • Pentostatin
  • Steroid-refractory graft-versus-host disease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Update on the management of acute graft-versus-host disease'. Together they form a unique fingerprint.

Cite this